Studies Seek to Find Female Biologic Factors That Affect HIV

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 10
Volume 10
Issue 10

BETHESDA, Maryland-A 5-year, $17.5-million program will investigate how HIV infection affects adolescent and adult women. Three research centers will house the Women’s HIV Pathogenesis Program, funded by the National Institute of Child Health and Human Development (NICHD). Researchers at the centers will collaborate with others in an effort to identify biologic factors unique to women that affect HIV.

BETHESDA, Maryland—A 5-year, $17.5-million program will investigate how HIV infection affects adolescent and adult women. Three research centers will house the Women’s HIV Pathogenesis Program, funded by the National Institute of Child Health and Human Development (NICHD). Researchers at the centers will collaborate with others in an effort to identify biologic factors unique to women that affect HIV.

The centers will be located at the University of Washington in Seattle, the Gladstone Institute of Virology in San Francisco, and Rush-Presbyterian-St. Luke’s Medical Center in Chicago.

Researchers will focus on various subpopulations, including minority women, lesbians, female substance abusers, and women approaching or experiencing menopause. Understanding biologic factors unique to women could provide insights into how they become infected with the virus and transmit it to others, how the disease progresses in women after infection takes place, and how the disease affects women differently from men, NICHD said.

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content